Showing 2 posts of 2 posts found.

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019
Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …

Pfizer image

SMC approves Inlyta

November 13, 2013
Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc

Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …

Latest content